Clinical Trial Update: Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating APL-2 in warm autoimmune hemolytic anemia and cold agglutinin disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Agglutinin Disease
• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• APL-2 (pegylated C3 inhibitor)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-12-12